Roche: FDA Approves Tecentriq With Fluoropyrimidine And Oxaliplatin For Adjuvant Treatment Of A Certain Type Of Stage III Colon Cancer
Tecentriq Plus Chemotherapy Reduces Risk Of Recurrence Or Death By 50% In Phase III ATOMIC Study
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA approves Genentech Tecentriq combo for stage III colon cancer adjuvant
Genentech said the FDA approved Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of a certain type of stage III colon cancer.